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ABSTRACT 
 
Purpose: The UK Clinical Practice Research Datalink (CPRD) is increasingly being used by 
Dutch researchers in epidemiology, and pharmaco-epidemiology. It is however unclear if CPRD 
is representative of the Dutch population and whether study results would apply to the Dutch 
population. Therefore, as first step, our objective was to compare the age and sex distribution of 
the CPRD with the total Dutch population. 
Methods: As a measure of representativeness, the age and sex distribution of the CPRD were 
visually and numerically compared with Dutch census data from the StatLine database of the 
Dutch National Bureau of Statistics in 2011. 
Results: The age distribution of men and women in the CPRD population was comparable to the 
Dutch male and female population. Differences of more than 10% occurred only occurred in 
older age categories (75+ in men, and 80+ in women). 
Conclusions: Results from observational studies that have used CPRD data are applicable to the 
Dutch population, and a useful resource for decision making in the Netherlands. Nevertheless, 
differences in drug exposure likelihood between countries should be kept in mind, as these could 
still cause variations in the actual population studied, thereby decreasing its generalizability. 
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INTRODUCTION 
The United Kingdom (UK) Clinical Practice Research Datalink (CPRD) is one of the world’s 
largest primary care databases, and is frequently used for post-authorisation safety studies, 
pharmaco-epidemiology, and disease epidemiology.1-5 Examples include the evaluation of side 
effects of dopamine agonists2 or diabetes drugs3,4, and the epidemiology of fractures.5 
From a global perspective, the healthcare system in the Netherlands, a small country not far from 
the UK, is largely comparable to that of the UK’s National Health Service (NHS); i.e. everyone 
has equal access to medical care regardless of income or socioeconomic status. In both countries, 
the general practitioner (GP) is the gatekeeper of the public healthcare system, meaning patients 
cannot refer themselves to secondary or tertiary care without the GP’s approval. These conditions 
are key for conducting population-based pharmaco-epidemiological studies.  
Although the Dutch public healthcare system has excellent conditions for establishing a large 
primary care database for pharmaco-epidemiological research that is comparable to the CPRD in 
terms of sample size, this has not yet occurred. Smaller primary care databases do exist (e.g. 
LINH (Netherlands Information Network of General Practice), IPCI (Integrated Primary Care 
Information), Pharmo Institute), however these are generally restricted by a limited set of medical 
codes (approximately 1000 different "International Classification of Primary Care" codes versus 
over 100,000 READ codes in the CPRD), few validation studies, considerable smaller sample 
size (e.g. 350.000 in LINH and 1.5 million in IPCI versus over 11 million in CPRD in 2011), and 
limited access to routinely collected lifestyle data, such as tobacco use, alcohol consumption, and 
socioeconomic status.6 Furthermore, claims that these data are representative for the total Dutch 
population are seldom supported by published figures.7,8 For these reasons, an increasing number 
of CPRD studies are being conducted by researchers from the Netherlands, and are financially 
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supported by Dutch universities and funding agencies such as ZonMw and NWO. A recent study 
showed that the CPRD is representative of the total UK population with respect to age and sex 
and covers 6.9% of the UK population.1,9 A wide range of diagnoses in the CPRD have been 
validated in a number of studies and data quality are further enhanced by NHS annual reward and 
incentive programme that details GP practice achievement results, the Quality and Outcomes 
Framework (QOF). The QOF awards GPs for regular recording of detailed data on a wide range 
of diseases. As a result, the CPRD contains millions of recordings for measurements such as 
blood pressure, cholesterol values and lung function. In addition, the strength of CPRD’s data 
partially explain why officials of the Food and Drug Administration in the United States perform 
studies using the CPRD database for drug safety monitoring and regulatory decision making.10-12 
Although there are many similarities between healthcare systems of the UK and the Netherlands, 
it is unclear whether results from CPRD studies would apply to the Dutch population. Therefore, 
our objective is to compare the age and sex distribution of the CPRD to the total Dutch 
population. 
  
6 
METHODS 
Using the same sample of data from the previously published CPRD data resource profile, the 
age and sex distribution of the CPRD primary care data on 27 March 2011 were visually and 
numerically compared with UK and Dutch census data in 2011.1 The CPRD (formerly known as 
Value Added Medical Products (VAMP), and later General Practice Research Database 
(GPRD)13,14) harnesses data from UK’s general practices and produces a primary care dataset 
since 1987. Through the years, it has become one of the largest databases of longitudinal medical 
records from primary care in the world, with coverage of over 11.3 million patients from 674 
practices. To date, 4.4 million active (alive, currently registered) patients meet quality criteria 
(approximately 6.9% of the UK population), who are broadly representative of the UK general 
population in terms of age, sex and ethnicity. For this study, visual comparison was performed by 
inspecting the overlap between the respective lines in a graph (Figure 1). An additional 
comparison calculated the differences between proportional distributions of 5-year age groups of 
CPRD data versus Dutch census data in 2011. We are not aware of any objective methods to 
define representativeness of patients in a research database compared to a country’s total 
population. We therefore described the absolute and proportional differences between the age and 
sex distributions of CPRD and Dutch Census data in order to leave this to the reader, and made a 
subjective decision to consider an age-sex specific difference of <10% representative (Table 1). 
Numbers for computing sex-stratified age categories of the total Dutch population in March 2011 
were obtained from the StatLine database of the Dutch National Bureau of Statistics 
(www.cbs.nl).  
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RESULTS 
In general, the age distribution of men and women in the CPRD population was comparable to 
the Dutch male and female population (Figure 1). Overall, the percentage men and women in the 
CPRD in 2011 was the same as in the Dutch population (49.5% men, 50.5% women). The 
additional comparison based on calculating the differences between proportional distributions of 
5-year age groups, showed that differences of more than 10% occurred only in older age 
categories, starting from 75+ in men, and 80+ in women (Table 1). 
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DISCUSSION 
In this study, we showed that the age and sex distribution the CPRD was visually and numerically 
comparable to that of the total Dutch population in 2011.  
To our knowledge, this is the first study to directly compare the age and sex distribution of the 
CPRD to the total Dutch population. Apart from LINH (Netherlands Information Network of 
General Practice), a national data network compiling electronic medical records (EMR) of 92 
primary care practices with 211 GPs and over 350,000 patients, we are not aware of any Dutch 
EMR database with data from GPs, which has published data on its representativeness according 
to the total Dutch population. The IPCI database is a longitudinal primary care database 
maintained by the department of Medical Informatics of the Erasmus Medical Centre in 
Rotterdam. In published papers of studies using the IPCI database it is frequently stated that the 
database is comparable to the total Dutch population in terms of age and sex.15,16 However, we 
could not verify this claim in a (peer-reviewed) publication. In a report of the Netherlands 
institute for health services research (NIVEL), which maintains the LINH database, it is shown 
that LINH is generally comparable to the total Dutch population, with a slight 
underrepresentation of women of 75 years and older.8 However, age- and sex-stratified 
proportions were calculated as compared to the total LINH population and not as compared to the 
total LINH population stratified by sex, making direct comparison with our results difficult.  
Our calculations of the differences between proportional distributions of 5-year age groups show 
that the CPRD is comparable to the Dutch population in terms of age and sex up to age 75 in men 
and age 80 in women. However, in Figure 1 it can be clearly seen that the age distribution of 
CPRD and Dutch census data almost overlap in these higher age groups. The large differences for 
higher age groups seen in Table 2 may be a spurious finding, since the calculations were based on 
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very small proportions of the total population. Of note, some difference is also seen between 
CPRD and the UK population in Figure 1. Men and to a lesser extent women aged between 20 
and 35 years of age are underrepresented in CPRD, which has been attributed to the fact that 
these individuals probably do not register with a GP.9 
Several strengths have to be noted for this study. First, UK CPRD data were compared to data 
from the StatLine database of the Dutch National Bureau of Statistics, a reliable source of 
population-based information, regulated by national and European codes and laws.17 Second, by 
calculating the differences between proportional distributions in all age groups, we demonstrated 
that the distributions were not only visually, but also numerically comparable. Lastly, by showing 
the overall representativeness of the CPRD database of another population besides the UK 
population, CPRD may be used as rich data source for healthcare policymakers outside the UK. 
There are also several limitations to this comparison. First of all, there are no objective methods 
to define representativeness of patients in a research database compared to a country’s total 
population. To overcome this, we gave the reader insight into the various ways of comparing 
these data. Furthermore, the CPRD population was compared to the total Dutch population in 
terms of age and sex only. Therefore, we cannot rule out differences in for instance ethnicity, 
socioeconomic class, or lifestyle, which may in turn impact disease prevalence, exposure to 
important risk factors, or the degree of health care seeking behaviour. Based on the report of the 
OECD health indicators, the UK population has higher rates of tobacco and alcohol consumption, 
and especially obesity among adults, compared to the Dutch population.18 Although the results of 
our study imply that the UK CPRD may also be representative of the total Dutch population, 
information on a specific population of drug-users is ultimately necessary to know whether a 
study’s results are transferrable to one’s own region. As of yet, we have not looked into the 
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comparability of various subpopulations in CPRD and The Netherlands. In addition, relative risks 
of disease outcomes found in CPRD could be extrapolated to the Dutch population, incidence 
rates or absolute risks cannot. 
In conclusion, this study showed that the age- and sex distribution of CPRD were generally 
comparable to that of the total Dutch population. Results from observational studies that have 
used CPRD data are applicable to the total Dutch population (similar to how relative risks from 
randomized clinical trials apply to their demarcated population), and a useful resource for 
decision making in the Netherlands. Nevertheless, differences in drug exposure likelihood 
between countries should be kept in mind, as these could still cause variations in the actual 
population studied, thereby decreasing its generalizability. In addition, the results of this study 
may encourage scientists from other countries with similar healthcare systems to perform 
comparable studies of CPRD representativeness. 
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Table 1. Differences between proportional age distributions of CPRD and the total Dutch population. 
 Total Men Women 
Age group CPRD NL Census Δa Δ%b CPRD NL Census Δa Δ%b CPRD NL Census Δa Δ%b 
0-4 4.99 5.54 -0.55 -9.94 5.15 5.72 -0.57 -9.98 4.82 5.35 -0.53 -9.90 
5-9 5.61 5.89 -0.28 -4.75 5.80 6.09 -0.29 -4.74 5.43 5.70 -0.27 -4.77 
10-14 5.68 6.00 -0.32 -5.38 5.87 6.20 -0.33 -5.32 5.49 5.80 -0.31 -5.43 
15-19 5.99 6.03 -0.04 -0.65 6.18 6.23 -0.05 -0.80 5.80 5.83 -0.03 -0.50 
20-24 5.83 6.23 -0.40 -6.44 5.98 6.35 -0.37 -5.89 5.68 6.10 -0.42 -7.00 
25-29 6.32 6.02 0.30 4.96 6.34 6.13 0.21 3.41 6.31 5.92 0.39 6.54 
30-34 6.51 6.03 0.47 7.83 6.57 6.11 0.46 7.65 6.44 5.96 0.48 8.01 
35-39 6.69 6.67 0.01 0.20 6.84 6.74 0.10 1.62 6.53 6.61 -0.08 -1.22 
40-44 7.59 7.77 -0.17 -2.22 7.80 7.91 -0.11 -1.42 7.39 7.62 -0.23 -3.03 
45-49 7.77 7.79 -0.02 -0.31 7.97 7.95 0.02 0.22 7.58 7.64 -0.06 -0.86 
50-54 6.95 7.19 -0.24 -3.41 7.12 7.30 -0.18 -2.44 6.78 7.09 -0.31 -4.38 
55-59 6.06 6.56 -0.49 -7.54 6.14 6.64 -0.50 -7.62 5.99 6.47 -0.48 -7.46 
60-64 6.15 6.64 -0.48 -7.24 6.16 6.72 -0.56 -8.30 6.15 6.55 -0.40 -6.18 
65-69 5.30 4.79 0.51 10.64 5.23 4.79 0.44 9.18 5.37 4.79 0.58 12.08 
70-74 4.03 3.83 0.20 5.27 3.87 3.67 0.20 5.31 4.19 3.98 0.21 5.23 
75-79 3.36 3.00 0.36 11.90 3.09 2.66 0.43 15.98 3.62 3.33 0.29 8.71 
80-84 2.56 2.17 0.39 18.00 2.15 1.70 0.45 26.28 2.97 2.64 0.33 12.80 
85-89 1.64 1.28 0.36 28.27 1.20 0.82 0.38 47.05 2.07 1.73 0.34 19.62 
90+ 0.98 0.57 0.41 70.52 0.55 0.27 0.28 102.20 1.40 0.87 0.53 60.92 
aAbsolute difference, bPercentage difference between CPRD versus NL Census data (CPRD minus NL Census, divided by NL Census), with >10% regarded as 
different. Abbreviations: CPRD: Clinical Practice Research Datalink; NL: Netherlands; Δ difference 
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Figure 1. Age distribution of the CPRD primary care data on 27 March 2011 compared with UK and NL 
Census data from 2011, in both men and women (top panel), men only (middle panel) and women only 
(bottom panel). These data are based on a one-million patient sample of CPRD. Adapted from Herrett et al. 
Int. J Epidemiol 2015. 
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FIGURE LEGENDS 
Figure 1. Age distribution of the CPRD primary care data on 27 March 2011 compared with UK 
and NL Census data from 2011, in both men and women (top panel), men only (middle panel) 
and women only (bottom panel). These data are based on a one-million patient sample of CPRD. 
Adapted from Herrett et al. Int. J Epidemiol 2015. 
